{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:30Z","timestamp":1786119630107,"version":"build-2736575974"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/mjt.0b013e3181ff7a9e","type":"journal-article","created":{"date-parts":[[2011,1,20]],"date-time":"2011-01-20T00:58:14Z","timestamp":1295485094000},"page":"133-144","source":"Crossref","is-referenced-by-count":9,"title":["Targeting the Proteasome With Bortezomib in Multiple Myeloma"],"prefix":"10.1097","volume":"19","author":[{"given":"James J.","family":"Driscoll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210202","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple Myeloma.","volume":"351","author":"Kyle","year":"2004","journal-title":"NEJM"},{"key":"R3-12-20210202","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1634\/theoncologist.11-1-51","article-title":"A practical update on the use of bortezomib in the management of multiple myeloma.","volume":"11","author":"San Miguel","year":"2006","journal-title":"Oncologist"},{"key":"R4-12-20210202","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd2269","article-title":"Multiple myeloma therapies.","volume":"6","author":"Strobeck","year":"2007","journal-title":"Nat Rev Drug Discovery"},{"key":"R5-12-20210202","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group.","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"R7-12-20210202","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome.","volume":"335","author":"Attal","year":"1996","journal-title":"New Eng J Med"},{"key":"R8-12-20210202","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.","volume":"348","author":"Child","year":"2003","journal-title":"N Eng J Med"},{"key":"R9-12-20210202","first-page":"846","article-title":"Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.","volume":"87","author":"Boccadoro","year":"2002","journal-title":"Haematologica"},{"key":"R10-12-20210202","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2141.2003.03948.x","article-title":"Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.","volume":"120","author":"Shaughnessy","year":"2003","journal-title":"Br J Haematol"},{"key":"R11-12-20210202","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"R12-12-20210202","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome.","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"R13-12-20210202","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"key":"R14-12-20210202","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents.","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"R15-12-20210202","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1158\/1078-0432.CCR-09-2882","article-title":"Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy.","volume":"16","author":"Wright","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R21-12-20210202","first-page":"1","article-title":"The expanding role of proteasome-based therapy in the treatment of hematologic malignancies.","volume":"1","author":"Driscoll","year":"2010","journal-title":"Open J Hematology"},{"key":"R22-12-20210202","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/leu.2010.129","article-title":"Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.","volume":"24","author":"Dispenzieri","year":"2010","journal-title":"Leukemia"},{"key":"R23-12-20210202","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2009-08-238196","article-title":"Hematopoietic stem cell transplantation for multiple myeloma beyond 2010.","volume":"115","author":"Blade","year":"2010","journal-title":"Blood"},{"key":"R24-12-20210202","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"},{"key":"R25-12-20210202","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of total therapy 3 (2003 -33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.","volume":"115","author":"Nair","year":"2010","journal-title":"Blood"},{"key":"R26-12-20210202","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br J Haematol"},{"key":"R27-12-20210202","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"R28-12-20210202","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2007.12.3323","article-title":"Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.","volume":"25","author":"Rosinol","year":"2007","journal-title":"J Clin Oncol"},{"key":"R29-12-20210202","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"key":"R30-12-20210202","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2008.06997.x","article-title":"Bortezomib, doxorubicin and dexamethasone (PAD) frontline treatment of multiple myeloma: updated results after long-term follow-up.","volume":"141","author":"Popat","year":"2008","journal-title":"Br J Haematol"},{"key":"R32-12-20210202","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2009.22.7561","article-title":"Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"R36-12-20210202","first-page":"837","article-title":"Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.","volume":"91","author":"Bruno","year":"2006","journal-title":"Haematologica"},{"key":"R37-12-20210202","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.exphem.2006.02.020","article-title":"Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.","volume":"34","author":"Kroger","year":"2006","journal-title":"Exp Hematol"},{"key":"R38-12-20210202","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.exphem.2009.03.008","article-title":"Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.","volume":"37","author":"Kroger","year":"2009","journal-title":"Exp Hematol"},{"key":"R42-12-20210202","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.","volume":"28","author":"Ladetto","year":"2010","journal-title":"JCO"},{"key":"R43-12-20210202","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/leu.2010.116","article-title":"Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.","volume":"24","author":"Kumar","year":"2010","journal-title":"Leukemia"},{"key":"R44-12-20210202","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"R45-12-20210202","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"R47-12-20210202","first-page":"2434","article-title":"Prospective, randomized study of single compared with double autologous transplantation for multiple myeloma: Bologna 96 clinical study. J Clin.","volume":"25","author":"Cavo","year":"2007","journal-title":"Oncol"},{"key":"R48-12-20210202","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood.V108.11.797.797","article-title":"Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: cancer and leukemia group B study 10301.","volume":"108","author":"Orlowski","year":"2006","journal-title":"Blood"},{"key":"R49-12-20210202","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.23487","article-title":"Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs.","volume":"112","author":"Barlogie","year":"2008","journal-title":"Cancer"},{"key":"R50-12-20210202","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1080\/10428190701540991","article-title":"Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.","volume":"48","author":"Oakervee","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R51-12-20210202","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"R52-12-20210202","first-page":"3859","article-title":"Bortezomib plus melphalan-prednisone continues to demonstrate a survival benefit vs melphalan-prednisone in the Phase III VISTA Trial in previously untreated multiple myeloma after 3 years follow-up and extensive subsequent therapy use.","volume":"114","author":"Mateos","year":"2009","journal-title":"ASH Ann Meet Abstr"},{"key":"R53-12-20210202","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1182\/blood-2008-07-167379","article-title":"Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo.","volume":"113","author":"Bruno","year":"2009","journal-title":"Blood"},{"key":"R54-12-20210202","first-page":"2771","article-title":"Bortezomib and dexamethasone as maintenance therapy in relapserefractory multiple myeloma patients. Blood.","volume":"112","author":"Benevolo","year":"2008","journal-title":"(ASH Annual Meeting Abstracts)"},{"key":"R55-12-20210202","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","article-title":"Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.","volume":"99","author":"Zhan","year":"2002","journal-title":"Blood"},{"key":"R56-12-20210202","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome I.","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"R57-12-20210202","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1158\/1078-0432.CCR-07-4568","article-title":"Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma.","volume":"14","author":"Burington","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R58-12-20210202","doi-asserted-by":"crossref","first-page":"7751","DOI":"10.1073\/pnas.86.20.7751","article-title":"E, Ganoth D, Armon T, et al. ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin.","volume":"86","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"R59-12-20210202","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1016\/S0021-9258(19)34041-4","article-title":"The proteasome (multicatalytic protease) is a component of the 1500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins.","volume":"265","author":"Driscoll","year":"1990","journal-title":"J Biol Chem"},{"key":"R60-12-20210202","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood-2010-04-281212","article-title":"Union of forces advances myeloma care.","volume":"116","author":"Stewart","year":"2010","journal-title":"Blood"},{"key":"R61-12-20210202","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrc1994","article-title":"Ubiquitin and ubiquitin-like proteins in cancer pathogenesis.","volume":"6","author":"Hoeller","year":"2006","journal-title":"Nature Rev Cancer"},{"key":"R62-12-20210202","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"key":"R63-12-20210202","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood-2009-03-211045","article-title":"The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.","volume":"115","author":"Driscoll","year":"2010","journal-title":"Blood"},{"key":"R64-12-20210202","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","article-title":"MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma.","volume":"116","author":"Milhollen","year":"2010","journal-title":"Blood"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00045391-201203000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:45:45Z","timestamp":1786041945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-201203000-00012"}},"subtitle":["Update on Therapeutic Benefit as an Upfront Single Agent, Induction Regimen for Stem-Cell Transplantation and as Maintenance Therapy"],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181ff7a9e","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}